SGLT inhibition and euglycaemic diabetic ketoacidosis

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 7, 2015, Pages 503-504

  Hine, Julia ^a   Paterson, Heather ^a   Abrol, Esha ^a   Russell Jones, David ^a   Herring, Roselle ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; INSULIN; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER;

ABDOMINAL PAIN; ADULT; BLOOD GAS ANALYSIS; CASE REPORT; CYSTADENOMA; DIABETIC KETOACIDOSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EUGLYCEMIC DIABETIC KETOACIDOSIS; FEMALE; HUMAN; KETONURIA; LETTER; MALE; METABOLIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS DISEASE; PANCREAS INSUFFICIENCY; PANCREAS RESECTION; PANCREATIC ATROPHY; PANCREATITIS; PRIORITY JOURNAL; VOMITING; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 84934443415     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00204-1     Document Type: Letter

References (8)

1. Dapagliflozin in combination therapy for treating type two diabetes. NICE technology appraisals (TA288) 2013, National Institute for Health and Clinical Excellence.
2. Lamos E, Younk L, Davis S Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2014, 23:875-882.
3. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015, 38:412-419.
4. Perkins A, Cherney D, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014, 37:1480-1483.
5. Bell D Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol 2015, 676191.
6. Dehn C SGLT inhibition in patients with type 1 diabetes. Lancet Diabet Endocrinol 2014, 2:539.
7. Ewald N, Bretzel RG Diabetes mellitus secondary to pancreatic diseases (Type 3c)-are we neglecting an important disease?. Eur J Intern Med 2013, 24:203-206.
8. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood FDA Drug Safety Communication, (accessed May 21, 2015). http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.